Biotech Market News
Novartis Bets $575M Upfront on Abogen’s mRNA T-Cell Engager
Novartis is paying $575 million upfront for a drug that has only been through small, early human studies, plus options on whatever Abogen builds next. That is the headline figure in a licensing and option agreement announced October 2, 2026 by Abogen Biosciences, a privately held mRNA developer based in Suzhou, China. Novartis gets exclusive…
Piramal Pharma Gets C$1.75M Ontario Grant for API Site
Ontario is picking up a third of the bill for a drug plant upgrade north of Toronto. Piramal Pharma Solutions, the contract development and manufacturing organization (CDMO) arm of Piramal Pharma Ltd. (NSE: PPLPHARMA; BSE: 543635), said on September 29 that its drug substance site in Aurora, Ontario, has been awarded $1,753,620 from the province’s…
Vimy Pharmaceuticals Raises C$12M Ahead of Planned TSXV Listing
Vimy Pharmaceuticals Inc. has closed a C$12.06 million brokered financing and signed a definitive agreement for its proposed reverse takeover of Harmony Acquisitions Corp. (TSXV: MONY.P), advancing the Canadian generic-drug developer toward a public listing. According to the September 28 announcement, Vimy issued 4,018,821 subscription receipts at C$3 each. The gross proceeds will remain in…
Zymeworks Completes $929M Theravance Acquisition, Adds YUPELRI Cash Flow
Zymeworks Inc. (Nasdaq: ZYME) completed its acquisition of Theravance Biopharma on September 23, adding commercial respiratory-drug revenue and additional royalty and milestone assets to its biotechnology portfolio. According to the closing announcement, Theravance is now a wholly owned Zymeworks subsidiary. Theravance shareholders received $17 in cash for each ordinary share, together with one non-tradeable contingent…
Telix to Buy Radioisotope Giant ITM for $1.65 Billion
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) said Sunday it has signed a definitive agreement to acquire ITM Isotope Technologies Munich SE, a privately held German company that makes the radioactive isotopes used in a growing class of cancer drugs called radiopharmaceuticals, or radioligand therapies. These drugs attach a radioactive isotope to a molecule that…
HUTCHMED Signs GSK Cancer Deal Worth Up to $1.3B
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) has entered an exclusive licensing agreement with GSK plc (NYSE/LSE: GSK) covering HMPL-A830, an experimental antibody-targeted cancer therapy expected to enter clinical development during the second half of 2026. Under the September 3 agreement, HUTCHMED is set to receive US$110 million upfront when the transaction closes. The company…
TScan Cuts 75% of Workforce and Pauses Phase 3 Trial
TScan Therapeutics Inc. (Nasdaq: TCRX) is eliminating approximately 75% of its workforce and pausing further enrollment in its Phase 3 ALLOHA-2 trial because it does not have sufficient capital to complete the study. The company announced the strategic reorganization on September 2. TScan will redirect its resources toward two preclinical in-vivo T-cell receptor-engineered T-cell therapy…
Rakovina Raises C$1.99M for AI-Designed Cancer Programs
Rakovina Therapeutics Inc. (TSXV: RKV; FSE: 7JO0) has completed an upsized private placement that raised aggregate gross proceeds of C$1.991 million to support its preclinical cancer-drug pipeline. According to the August 31 financing announcement, the company issued 19.91 million units at C$0.10 each across two tranches. Each unit contained one common share and one-half warrant.…
Astellas Joins U.S. Most Favored Nation Pricing Program
Astellas Pharma Inc. (TSE: 4503) announced on August 31 that it has entered a voluntary drug pricing agreement with the U.S. government. The release itself is unusually thin on specifics, disclosing just two actions and stating plainly that additional terms are not being disclosed, so this article draws on independent reporting to explain what program…
DualityBio, Genentech Team Up on Next-Gen ADC Payloads
DualityBio Inc. (HKEX: 09606) announced on August 28 that it has entered a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates (ADCs) built on DualityBio’s proprietary DUPAC payload platform. Unlike several recent biotech licensing deals that disclosed no financial terms, this one comes with real numbers:…
